ClinicalTrials.gg
RecruitingNCT06142669Updated Jan 22, 2024

EVOLUTION® Revision STEMMED CS Post Market Clinical Follow-up Study Protocol

An observational study in Joint Diseases, sponsored by MicroPort Orthopedics Inc.. Recruiting at 1 site in Italy. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.

Planned enrollment
15th of 20
45 · median 69
Started
2023
the only one that year
Observational
20 of 21
5 open now
Primary completion
2036-06
later than 12 of 12 live
Registered
20th of 21
by date

Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 15th largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2023, is one of 20 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 20th registered.

Joint Diseases

386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.

Browse Joint Diseases studies →

Open to participants now

5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Joint Diseases by MicroPort Scientific Corporation, or all of them as a file.
02

Study summary

MicroPort (MPO) is conducting this PMCF study to evaluate the safety and effectiveness of its EVOLUTION® Revision Tibial System and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert. This type of study is required by regulatory authorities for all devices that have been approved in Europe to evaluate the medium and long-term clinical evidence.

Read the detailed description

The primary objective of this study is to estimate individual component survivorship for tibial base, femoral component, and tibial insert at specified intervals out to 10 years follow-up.

The secondary objectives include:

  • Determine the cumulative incidence of individual component revision at specified intervals out to 10 years follow-up;
  • Characterize functional scores for subjects, as assessed by KOOS Scores and EQ-5D-5L Scores, out to 10 years follow-up;
  • To assess subject satisfaction with their TKA procedure using the Forgotten Joint Score and a Satisfaction Survey;
  • To assess the presence, zone, and the size of radiolucencies surrounding implanted components out to 10 years follow-up;
  • To assess safety and characterize protocol defined adverse events and adverse device effects.
03

Conditions studied

  • Joint Diseases

Keywords

  • Knee Osteoarthritis
  • Revision Procedure
  • Knee arthroplasty
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Multicenter, prospective follow-up study of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 3 years (+ 6 months) of the study index surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has previously undergone or currently has been determined to undergo a revision knee arthroplasty that requires implantation of the components under study (EVOLUTION® Revision Tibial System and EVOLUTION® STEMMED CS Femur with the EVOLUTION® MP CS Tibial Insert)
  2. Decision to perform the study index surgery with the required study components is pre-determined regardless of the research;
  3. Previously implanted subjects must be enrolled within 3 years (+ 6 months) of their study index surgery
  4. Willing to voluntarily sign the form
  5. Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit.

Exclusion criteria

Exclusion Criteria:

  1. Skeletally immature (less than 21 years of age) at time of implantation
  2. Has or had an overt infection at the time of implantation
  3. Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
  4. Currently enrolled in another clinical investigation which could affect the endpoints of this protocol
  5. Has or had documented substance abuse issues
  6. Has or had an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  7. Currently incarcerated or has impending incarceration
  8. Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • Revision Total Knee Arthroplasty

    Single study group with either newly or previously implanted subjects with the EVOLUTION® Revision Tibia and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Insert.

    Device: EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert

Interventions

  • DeviceEVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert

    Primary knee arthroplasty or a revision knee that requires a revision procedure.

06

What researchers measure

Primary outcomes

  1. The proportion of EVOLUTION® Revision Tibial Base components survivorship out to 10 years.

    Percentage of knees survived with no revision or replacement at 10-year

    Time frame: up to 10 years

  2. The proportion of EVOLUTION® STEMMED CS Femoral components survivorship out to 10 years.

    Percentage of knees survived with no revision or replacement at 10-year

    Time frame: up to 10 years

  3. The proportion of EVOLUTION® MP CS tibial inserts survivorship out to 10 years.

    Percentage of knees survived with no revision or replacement at 10-year

    Time frame: up to 10 years

Secondary outcomes

  1. Functional Scores

    To assess functional scores utilizing Knee Injury and Osteoarthritis Outcome Score (KOOS Scores) out to 10 years follow-up.

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

  2. Functional Scores

    To assess subject satisfaction with their Total Knee Arthroplasty (TKA) procedure utilizing the Forgotten Joint Score (FJS) at specified intervals out to 10 years follow-up.

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

  3. Functional Scores

    To assess functional scores utilizing EQ-5D-5L at specified intervals out to 10 years follow-up.

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

  4. Subject Satisfaction

    To assess subject satisfaction with their TKA procedure via the Satisfaction Survey at specified intervals out to 10 years follow-up.

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

  5. Radiolucencies

    To assess the presence of radiolucencies surrounding the implanted components at specified intervals out to 10 years follow-up.

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

  6. To assess subject safety: Adverse Events o Adverse Events related to study device or the index surgical procedure

    To assess safety and characterize protocol defined adverse events and adverse device effects.

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

  7. Incidence of component revision

    Determine the cumulative incidence of individual component revision at specified intervals out to 10 years follow-up.

    Time frame: Year 1,Year 3, Year 5, Year 7, and Year 10

07

Study locations

1 of 1 sites recruiting
  • Gaetano Pini Orthopedic Institute
    Milan, Piazza C. Ferrari 1 20122 Milan, Italy
    Recruiting
    • Pietro Randelli, Prof · Contactpietro.randelli@unimi.it · +39-335-5292-622
    • Pietro Randelli, Prof · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jun 2036, 152 months after the start.

Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 152 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Nov 21, 2023
StartActual
Oct 31, 2023
Primary completionEst.
Jun 2036
CompletionEst.
Dec 2036
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06142669
Responsible party
Sponsor
First posted
Nov 21, 2023
Start date
Oct 31, 2023
Primary completion
Jun 2036 (estimated)
Completion
Dec 2036 (estimated)
Last update
Jan 22, 2024

Study contacts

JoAnna-Marie N Becker, BS
Contact
joannamarie.becker@ortho.microport.com
+1 901 290 5280
Pietro Randelli, Prof
Contact
pietro.randelli@unimi.it
+39-335-5292-622
Pietro I Randelli, Prof
principal investigator · Gaetano Pini Orthopedic Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion